Jeremy N. Rich
Molecular Biology · 2004–2019
A researcher in the Science corpus: 15 papers; trusts 7 researchers and is trusted by 13 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 204 citations into it
- Oncology — 165 citations into it; #236 of 1,698 by trust here, #209 by citations
- Genetics — 133 citations into it; #2,286 of 6,854 by trust here, #378 by citations
- Cancer Research — 113 citations into it; #490 of 1,780 by trust here, #296 by citations
- Developmental Neuroscience — 54 citations into it
- Cellular and Molecular Neuroscience — 10 citations into it
Whom Jeremy N. Rich trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Jeremy N. Rich overall
Papers from Jeremy N. Rich's perspective
Ordered by how strongly the researchers Jeremy N. Rich trusts endorse each paper. Same corpus, a different order for every researcher.
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage response (Nature)
- Efficient tumor formation by single human melanoma cells (Nature)
- Human cortical glial tumors contain neural stem‐like cells expressing astroglial and neuronal markers in vitro (Glia)
- A perivascular niche for brain tumor stem cells. (Cancer Cell)
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy (Science)
- Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. (Cancer Cell)
- Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. (New England Journal of Medicine)
- Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. (Cancer Cell)
- Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. (Cell Stem Cell)
- Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. (Cancer Cell)
Their papers
- Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma (2007) — 1,087 citations
- Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. (2008) — 747 citations
- Phase II trial of gefitinib in recurrent glioblastoma. (2004) — 761 citations
- Periostin Secreted by Glioblastoma Stem Cells Recruits M2 Tumor-associated Macrophages and Promotes Malignant Growth (2015) — 839 citations
- Challenges to curing primary brain tumours (2019) — 771 citations
- Cancer stem cells in glioblastoma (2015) — 1,484 citations
- Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells (2013) — 777 citations
- Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth (2013) — 852 citations
- Integrin alpha 6 regulates glioblastoma stem cells (2010) — 680 citations
- The Hypoxic Microenvironment Maintains Glioblastoma Stem Cells and Promotes Reprogramming towards a Cancer Stem Cell Phenotype (2009) — 784 citations
- Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells (2009) — 1,318 citations
- Making a tumour's bed: glioblastoma stem cells and the vascular niche (2007) — 748 citations
- Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. (2007) — 1,395 citations
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage response (2006) — 6,322 citations
- Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. (2006) — 1,367 citations